Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women

Maturitas

Volumn 42, Issue 3, 2002, Pages 233-242

  Manassiev, N A ^a   Godsland, I F ^b   Crook, D ^c   Proudler, A J ^b   Whitehead, M I ^a   Stevenson, J C ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Dydrogesterone; Hormone replacement therapy; Insulin resistance; Insulin secretion; Lipids; Oestradiol

Indexed keywords

C PEPTIDE; DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL; GLUCOSE; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; DYDROGESTERONE; LIPID; PROGESTERONE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY FAT; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INSULIN METABOLISM; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND; ANALYSIS OF VARIANCE; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PULSATILE FLOW; RADIODENSITOMETRY; THEORETICAL MODEL;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; C-PEPTIDE; CAROTID ARTERIES; DENSITOMETRY, X-RAY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; FEMALE; HUMANS; HYSTERECTOMY; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MIDDLE AGED; MODELS, THEORETICAL; POSTMENOPAUSE; PROGESTERONE CONGENERS; PULSATILE FLOW; TRIGLYCERIDES;

EID: 0037173737     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00069-5     Document Type: Article

References (39)

1. The influence of female sex steroids on glucose metabolism and insulin action
2. Estrogen replacement therapy: A quantitative assessment of the epidemiologic evidence
3. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
5. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
6. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus
7. The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus
8. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
9. Is there a menopausal metabolic syndrome?
10. Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins
11. Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy
12. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin
13. The effects of hormone replacement therapy on insulin sensitivity in surgically postmenopausal cynomolgus monkeys (Macaca fascicularis)
14. Effects on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone
15. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone on lipid metabolism
16. Hormone replacement therapy with dydrogesterone progestin and estradiol-17β: Effects on serum lipoproteins and on glucose tolerance during 24 month follow-up
17. Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); Results from a one-year study in postmenopausal women
18. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women
19. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: Relation to their insulinemic secretion
20. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause
21. Determination of blood glucose using an oxidase-peroxidase system with non-carcinogenic chromogen
22. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol
23. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure
24. Immunoturbidimetric assays for serum apoproteins A1 and B using Cobas Bio centrifugal analyser
25. Quantitative estimation of insulin sensitivity
26. Evaluation of four mathematical models of glucose and insulin dynamics with analysis of the effects of age and obesity
27. Assessment of insulin sensitivity in man: A comparison of minimal model and euglycaemic clamp derived measures in health and heart failure
28. Quantitative estimation of beta cell sensitivity to glucose in the intact organism
29. Calculated pattern of intraportal insulin appearance without independent assessment of C-peptide kinetics
30. Prehepatic beta-cell secretion during the intravenous glucose tolerance test in humans: Application of a combined model of insulin and C-peptide kinetics
31. Evaluation of two methods for estimating pancreatic insulin secretion by modelling analysis of the intravenous glucose tolerance test
32. An apparently anomalous relationship between insulin and C-peptide concentrations in their initial response to intravenous glucose
33. Sex- and menopause-associated changes in body fat distribution
34. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate
35. The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids
36. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
37. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause
38. The effect of transdermal 17-beta-estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration
39. Effects of oral and transdermal 17 beta estradiol with cyclical norethindrone acetate on insulin sensitivity, secretion and elimination in postmenopausal women